Thoroughbred Financial Services’s Teva Pharmaceuticals TEVA Stock Holding History

Thoroughbred Financial Services’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$239K	Hold	7,054	–	–	0.01%	578
2026 Q1	$212K	Sell	7,054 -442	-6%	-$14.2K	0.01%	555
2025 Q4	$233K	Buy	+7,496	New	+$185K	0.01%	525
2025 Q2	–	Sell	-17,917	Closed	-$275K	–	696
2025 Q1	$275K	Hold	17,917	–	–	0.02%	575
2024 Q4	$394K	Sell	17,917 -715	-4%	-$13K	0.02%	475
2024 Q3	$335K	Buy	18,632 +1,040	+6%	+$18.2K	0.02%	494
2024 Q2	$285K	Buy	17,592 +2,200	+14%	+$33.9K	0.02%	515
2024 Q1	$217K	Sell	15,392 -2,408	-14%	-$30.4K	0.02%	430
2023 Q4	$185K	Sell	17,800 -1,440	-7%	-$13.4K	0.01%	580
2023 Q3	$196K	Sell	19,240 -16,070	-46%	-$150K	0.02%	552
2023 Q2	$265K	Sell	35,310 -69,067	-66%	-$560K	0.03%	351
2023 Q1	$923K	Sell	104,377 -52	-0%	-$514	0.14%	164
2022 Q4	$952K	Buy	104,429 +79,219	+314%	+$691K	0.16%	150
2022 Q3	$203K	Buy	+25,210	New	+$223K	0.04%	347

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Thoroughbred Financial Services's TEVA Position: Q2 2026 in Review

Thoroughbred Financial Services held its Teva Pharmaceuticals (TEVA) position steady in Q2 2026 at 7,054 shares worth $239K. The position accounts for 0.01% of the portfolio, ranked #578.

Thoroughbred Financial Services first reported a position in TEVA in Q3 2022 and has held it in 14 quarters since. The position peaked at $952K in Q4 2022. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Thoroughbred Financial Services held 7,054 shares of Teva Pharmaceuticals worth $239K as of Q2 2026.
Thoroughbred Financial Services left its Teva Pharmaceuticals share count unchanged in Q2 2026.
Teva Pharmaceuticals made up 0.01% of Thoroughbred Financial Services's portfolio in Q2 2026, its #578 holding.
Thoroughbred Financial Services first reported a position in Teva Pharmaceuticals in Q3 2022 and has held it in 14 quarters since.
Thoroughbred Financial Services's Teva Pharmaceuticals position peaked at $952K in Q4 2022.
673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Thoroughbred Financial Services's 13F filing for Q2 2026, filed 11 Aug 2026.